FedCircuitBlog

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• a post commenting on the Federal Circuit’s rehearing grant rates and how to achieve rehearing at the court;
• discussion of a letter sent by two U.S. senators to the U.S. Patent and Trademark Office concerning patent law’s disclosure requirements; and
• an article discussing a recent case addressing subject matter eligibility of software claims based on improvement to computer functionality.

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• an article discussing the long-term impact of the Federal Circuit’s decision concerning two patents covering the drug Eliquis;
• a report detailing the ITC’s urging of the Federal Circuit to uphold its ruling of infringement of Jeep’s trade dress;
• an article discussing a recent bid protest in the context of challenging government agency decisions; and
• a report focusing on a precedential order by the Federal Circuit regarding the PTAB’s conclusion that it is not bound by agreements to arbitrate validity disputes.

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• commentary on the swearing in of new Federal Circuit Judge Tiffany P. Cunningham;
• discussion of a recent precedential Federal Circuit opinion applying the limitation on patent damages found in 35 U.S.C. § 287(a); and
• an article discussing the Federal Circuit’s determination that appointments to the Trademark Trial and Appeal Board do not violate the Appointments Clause.

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• a report discussing the Federal Circuit’s refusal to consider a ruling addressing alleged venue manipulation;
• an article about a Federal Circuit opinion addressing alleged inequitable conduct in the procurement of a patent; and
• an article discussing difficulty in the application of the non-obviousness patentability requirement in the context of design patents.

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• a Federal Circuit opinion reversing a $1.2 billion dollar jury verdict;
• the use of court-appointed technical advisors by federal district courts in patent cases;
• how the Federal Circuit affirmed a district court’s order prohibiting certain expert testimony related to damages in a patent case; and
• a Federal Circuit opinion in a patent case addressing the construction of a claim preamble.

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• an article discussing the filing of an amicus brief in the aftermath of the Federal Circuit’s recent treatment of “skinny labels;”
• a conversation about President Biden’s potential federal court nominations based on previous picks and patterns; and
• an article discussing how steel importers are urging the Federal Circuit to reverse a panel decision upholding levies on steel imports.

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• an article discussing how the Patent Office “let’s women shine in court while Big Law sends men,”
• commentary on a Federal Circuit decision addressing the timeline limitations on interlocutory appeals,
• a blog post discussing a transition in the position of the Deputy Director of the USPTO, and
• an article highlighting a Federal Circuit case that may determine an Appointments Clause challenge to the members of the Merit Systems Protection Board.

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights an article discussing a Federal Circuit decision upholding three patents concerning antibody treatment for migraines, another article highlighting a summary affirmance of a district court’s invalidation of a patent for ineligibility, an article about a Federal Circuit determination that the Patent Office cannot recoup expert witness fees in lawsuits filed in district court by unsuccessful patent applicants, and commentary on a recent ruling about the applicability of the Administrative Procedure Act in the context of inter partes review proceedings.

Federal Circuit Upholds Teva-GlaxoSmithKline Decision, Landing Another Blow to ‘Skinny’ Labels – On EndPointsNews, Zachary Brennan wrote about the Federal Circuit’s most recent disposition in the case GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. and its impact on generic drug competition.

CAFC Again Says Teva Induced Infringement on Carvedilol, Assures Holding Narrowly Applies – Eileen McDermott also reports on GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., noting that the Federal Circuit “underscored its October 2020 ruling.”

Fed Circ Upholds VA Cutoff On Resuming Disability Benefits – Barbara Grzincic wrote an article for Reuters explaining the Federal Circuit’s decision in Buffington v. McDonough.

Is the Federal Circuit Too Trigger-Happy Invalidating Means Claims? – This question is asked by Dennis Crouch on PatentlyO, where Crouch focuses on “an interesting petition to the Supreme Court focusing on indefiniteness and means-plus-function claims.”

Apple Must Face Apple Watch Patent Claims, Fed Circ. Affirms – Blake Brittain posted an article on Reuters.com about how Apple “lost its bid to escape patent infringement claims over its Apple Watch technology . . . at the U.S. Court of Appeals for the Federal Circuit.”

Teva’s Generic Label Not Skinny Enough to Protect from $234M Damages to GSK – In an article written by Khadijah M. Silver on MedCityNews.com, Silver reports that the Federal Circuit issued a “controversial” decision about Teva’s “skinny label.”